DT
HealthMore in Health→
A CAR-T result in high-risk smoldering multiple myeloma points to a more aggressive early-treatment debate
A single infusion of ciltacabtagene autoleucel reportedly produced a 100% MRD-negativity rate in patients with high-risk smoldering multiple myeloma, an outcome that could intensify discussion around how early advanced c
Key Takeaways
- Medical Xpress reports that a single infusion of ciltacabtagene autoleucel led to a 100% MRD-negativity rate in the studied group.
- The reported patients had high-risk smoldering multiple myeloma.
DE
DT Editorial Team··via medicalxpress.com